Literature DB >> 28090158

Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA.

Mina Awad, Pavit Singh, Olga Hilas.   

Abstract

Zarxio (filgrastim-sndz), a biosimilar for the treatment of severe chronic neutropenia.

Entities:  

Year:  2017        PMID： 28090158      PMCID： PMC5215272     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  1 in total

1.  Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.

Authors:  K Blackwell; V Semiglazov; D Krasnozhon; I Davidenko; L Nelyubina; R Nakov; G Stiegler; P Singh; A Schwebig; S Kramer; N Harbeck
Journal:  Ann Oncol       Date:  2015-06-28       Impact factor: 32.976
  1 in total
  1 in total

1.  Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?

Authors:  Nadine Abdallah; Seongho Kim; Lois Ayash; Scott Klimecki; Marie Ventimiglia; Asif Alavi; Voravit Ratanatharathorn; Joseph Uberti; Abhinav Deol
Journal:  Bone Marrow Transplant       Date:  2019-11-18       Impact factor: 5.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.